clinical trial · NCT05227690
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
AbbVie·phase2·completed·n = 385
SchizophreniaPlaceboEmraclidine 10 mgEmraclidine 30 mg
brief summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
started
Jun 30, 2022
primary completion
Aug 23, 2024
completion
Aug 26, 2024
last updated
Sep 17, 2025
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol